|1.||Suzuki, Kokichi: 3 articles (05/2009 - 05/2004)|
|2.||Iida, Hiroyuki: 3 articles (05/2009 - 05/2004)|
|3.||Muto, Yuko: 3 articles (05/2009 - 05/2004)|
|4.||Ishii, Hidemi: 3 articles (05/2009 - 05/2004)|
|5.||Kato, Emiko: 2 articles (05/2009 - 05/2004)|
|6.||Itoh, Fumi: 1 article (05/2009)|
|7.||Sakakibara, Shiro: 1 article (05/2009)|
|8.||Kakui, Nobukazu: 1 article (05/2009)|
|9.||Nomoto, Masahiro: 1 article (05/2004)|
|10.||Fushihara, Kenichi: 1 article (05/2004)|
05/01/2009 - "We performed the pharmacologic study to assess the effect of EF6265, a specific inhibitor of activated form of TAFI (TAFIa) on sepsis-induced organ dysfunction models. "
05/01/2009 - "In the sepsis model, EF6265, simultaneously administered with ceftazidime (CAZ) 2 hours after Pseudomonas aeruginosa injection, showed no influence on the antibiotic activity of CAZ. "
05/01/2009 - "EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats."
01/01/2007 - "In the present study, the effects of EF6265, a novel specific plasma carboxypeptidase B inhibitor, on renal dysfunction in a rat thrombotic glomerulonephritis model were examined. "
01/01/2007 - "EF6265, which inhibits plasma carboxypeptidase B, showed a protective effect on thrombotic renal dysfunction in thrombotic glomerulonephritis through enhancing the fibrinolysis."
01/01/2007 - "EF6265, a novel plasma carboxypeptidase B inhibitor, protects against renal dysfunction in rat thrombotic glomerulonephritis through enhancing fibrinolysis."
05/01/2004 - "To target thrombosis in a new way, we have identified and optimized a phosphinic acid-containing inhibitor of CPB, EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino) propyl]hydroxyphosphinoyl]methyl]heptanoic acid] and determined both the pharmacological profile and pathophysiological role of CPB in rat thrombolysis. "
|4.||Carboxypeptidase U (TAFI)
|5.||Phosphinic Acids (Phosphinic Acid)
|6.||Fibrinogen (Factor I)